alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
#### Jin Zhen CHEN, Petitioner, v. UNITED STATES DEPARTMENT OF JUSTICE, Alberto GONZALES,1 United States Attorney General, Respondent.

No. 03-41046-AG NAC.

United States Court of Appeals, Second Circuit.

Oct. 26, 2005.

Yee Ling Poon (Robert Duk-Hwan Kim, on the brief), Law Offices of Yee Ling Poon, New York, NY, for Petitioner.

Andrew Byerly Birge, United States Attorney’s Office, Western District of Michigan, Grand Rapids, MI, for Respondent.

*86PRESENT: LEVAL, STRAUB, and HALL, Circuit Judges.

1

. Pursuant to Federal Rule of Appellate Procedure 43(c)(2), Alberto Gonzalez is substituted for his predecessor, John Ashcroft, as Attorney General of the United States.

Petitioner Jin Zhen Chen (“Chen”) petitions for review from the November 2003 final order of removal of the BIA affirming, without opinion, the decision of the Immigration Judge (“IJ”) denying her claims for asylum, withholding of removal, and Convention Against Torture (“CAT”) relief. We assume the parties’ familiarity with the facts and procedural history of the case.

Where, as in this case, the BIA affirms, without opinion, the decision of the IJ, we review the IJ’s factual findings and credibility determinations under the substantial evidence standard; “a finding will stand if it is supported by reasonable, substantial, and probative evidence in the record when considered as a whole.” *Secaida-Rosales v. INS,*331 F.3d 297, 307 (2d Cir.2003) (internal quotations omitted); *see Dong v. Ashcroft,*406 F.3d 110, 112 n. 1 (2d Cir.2005) *(per*curiam).

In this case, the IJ denied Chen’s application based solely on an adverse credibility finding, namely, because of the lack of specificity in her testimony. The IJ’s decision in this regard is not supported by substantial evidence. The IJ erred in finding that Chen’s asylum application and testimony were inconsistent. Chen provided detailed testimony regarding her forced IUD insertion, hiding from the authorities, and telling the cadres that she was too weak to be sterilized when they first wanted to take her for sterilization. Moreover, Chen’s failure to recall the specific date of her sterilization, “which reveals] nothing about [her] fear of ... safetyf,] ... [is a] minor inconsistency] that cannot form the basis of an adverse credibility finding.” *Bandari v. INS,*227 F.3d 1160, 1166 (9th Cir.2000) (internal quotations and citations omitted). She was able to recall that her sterilization occurred two weeks after the birth of her second child, who was born on April 26, 1994.

Further, on remand, the BIA should make a specific finding with regard to Chen’s CAT claim.

Accordingly, we grant Chen’s petition, vacate the BIA’s order and remand to the BIA for further proceedings.
1 

Date: November 8, 2011 

From: Agency for Toxic Substances and Disease Registry 

Subject: Comments on EPA’s Toxicological Review of Ammonia

To: Environmental Protection Agency 

ATSDR’s Division of Toxicology and Environmental Medicine (DTEM) has completed a 

review of the IRIS toxicological review of ammonia. We appreciate the opportunity to 

comment. Overall, EPA’s document is very thorough and well written; therefore we 

have only a few minor comments. 

ATSDR has a Toxicological Profile for Ammonia that was published in 2004. ATSDR 

has two inhalation Minimal Risk Levels (MRLs) for ammonia: an acute inhalation MRL 

of 1.7 ppm and a chronic inhalation MRL of 0.1 ppm. While ATSDR has an acute 

inhalation MRL, EPA has not developed an acute RfC. ATSDR’s chronic MRL is based 

on the same study (Holness et al. 1989) that EPA used to base their proposed chronic RfC 

of 0.3 mg/m3

(0.4 ppm). For the chronic MRL, ATSDR used the mean TWA ammonia 

concentration of 9.2 ppm from the Holness et al. (1989) study, adjusted for continuous 

exposure and divided by an uncertainty factor of 10 for protection of sensitive individuals 

and a modifying factor of 3 for lack of reproductive and developmental studies. EPA’s 

proposed RfC is based on the high exposure category of 12.5 ppm (8.8 mg/m3

) from the 

Holness et al. (1989) study, adjusted for continuous exposure and divided by an 

uncertainty factor of 10 to account for potentially susceptible individuals. Overall, the 

values use a slightly different NOAEL but the EPA chronic RfC is similar to the ATSDR 

chronic MRL for ammonia. Therefore, we have no objections to EPA’s conclusions. 

 

Specific Comments: 

Page 8, Line 30 – Souba 1987 is cited referring to Figures 3-1 and 3-2. Should this 

citation be Nelson and Cox (2008) as stated in the footnote for these two figures? 

Page 16, Line 35 – Add 40 ppm to list of exposure levels. See page C-35. 

Page 17, Line 7 – Consider adding “However, brief exposure to 150-200 ppm produced 

lacrimation and transient discomfort”, as stated on page C-33. 

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service 

Agency for Toxic Substances 

 and Disease Registry 

Memorandum 
Page 28, Line 24 – Suggest replacing “over a long period of time” with “duration not 

specified”. 

Page 38, Section 4.3 Reproductive/Developmental Studies – Consider adding Minana et 

al. 1995 to discussion. Miñana MD, Marcaida G, Grisolia S, et al. 1995. Prenatal 

exposure of rats to ammonia impairs NMDA receptor function and affords delayed 

protection against ammonia toxicity and glutamate neurotoxicity. J Neuropathol Exp 

Neurol 54(5):644-650. 

Overall, we consider the questions in the Charge to External Reviewers appropriate.
- All
            - Title
            - Author
            - Subject
            - Date
            - Full-Text

            -                              Explore                            ******                - Educational Resources
              - Archival Collections
              -                                      Themes                                    ******                  - Economic Data
                - Federal Reserve
                - View all 
              - Timelines 
            -                              Browse                            ******                - Titles
              - Authors
              - Subjects
              - Dates 
            -                              About                            ******                - About FRASER
              - FAQ
              - Contact Us
              -                                      FRASER API                                    ******                  - REST API
                - OAI-PMH 
            - Inside FRASER Blog

            - **

Home                 > Browse by Title > Series of Studies on Employment of Women in Various Defense Industries

              																								United States. Women's Bureau.						"Women's Employment in Artillery Ammunition Plants, 1942 : Women's Bureau Bulletin, No. 192-2" in *Series of Studies on Employment of Women in Various Defense Industries : Women's Bureau Bulletin, No. 192*			(1942).						https://fraser.stlouisfed.org/title/5465/item/539654, accessed on September 25, 2024.	    

        - **FRASER**
        - About
        - FAQ
        - Legal and Privacy
        - FRASER API

          -                              @FedFRASER 
          - ** Contact Us
          -  **  What's New  
          -  **  Inside FRASER
# Materials Not Included in **Airworthiness Directive (AD) Docket**

Docket Number: FAA- 2012 - 0110 Directorate Identifier: 2011NM148AD

GOODRICH 30255 - 0201 -28 - 01, R2 --- 10/21/11 GOODRICH 30255 - 0201 -28 - 01, R1 --- 6/7/11 GOODRICH ICA T3044 - 0010 - 0101, RC --- 5/13/11

Name/Description of Item(s) Not Included in FDMS Docket and Maintained in the Supplemental AD Docket 

### MA **Y BE VIEWED AT:** Federal Aviation Administration

Transport Airplane Directorate Rules Docket 1601 Lind Ave. SW., Renton, WA 98057 425.227.1221 **DURING THE HOURS OF:** 9 a.m. and 3 p.m., Monday through Friday, except Federal holidays. Form Date: 03/05/2008
UNITED STATES ENVIRONMENTAL PROTECTION AGENCY 

WASHINGTON, D.C. 20460 

OFFICE OF 

AIR AND RADIATION 

MEMORANDUM 

Subject: Summary of Stakeholder Meetings 

From: Kristien Knapp 

To: Dockets EPA-HQ-OAR-2013, EPA-HQ-OAR-2013-0603, and EPA-HQ-OAR2013-0495 

This memorandum summarizes meetings with stakeholders during the week of July 28, 2014. 

On July 28, Acting Assistant Administrator for Air and Radiation Janet McCabe and Associate 

Assistant Administrator for Climate and Senior Counsel for Air and Radiation Joseph GotTman 

met with Susan Tierney ofthe Analysis Group. Ms. McCabe and Mr. Goffman answered 

questions about the Clean Power Plan proposals. 

On July 28, Associate Assistant Administrator for Climate and Senior Counsel for Air and 

Radiation Joseph Goffman met with representatives of the National Rural Electric Cooperative 

Association. Mr. Goffman and EPA staff answered questions about the Clean Power Plan 

proposals. Sign-in sheet attached. 

On July 29, Deputy Associate Administrator for Intergovernmental Relations Mark Rupp 

participated in meeting of state agency representatives organized by the Georgetown Climate 

Center. Participants included: 

• Dan Utech, White House Special Assistant to the President for Energy and Climate 

Change 

• Craig Segal, Senior Staff Attorney, California Air Resources Board 

• Rob Klee, Commissioner, Connecticut Department of Energy and Environmental 

Protection 

• Katie Dykes, Deputy Commissioner for Energy, Connecticut Department of Energy and 

Environmental Protection 

• Ali Mirzakhalili, Division Director, Division of Air Quality, Delaware Department of 

Natural Resources and Environmental Control 

• David Thornton, Assistant Commissioner, Minnesota Pollution Control Agency 

• Tracy Stone-Manning, Director, Montana Department of Environmental Quality 

• Jared Snyder, Assistant Commissioner for Air Resources, Climate Change and Energy, 

New York State Department of Environn1ental Conservation 

• Anthony Belsito, Policy Advisor to the Chair, New York State Department of Public 

Service 

Internet Address (URL) • http://www.epa.gov 

Recycled/Recyclable • Printed with Vegetable Oil Based Inks on 100% Postconsumer, Process Chlorine Free Recycled Paper 
• Dick Pedersen, Director, Oregon Department of Environmental Quality 

• Deb Markowitz, Secretary, Vermont Agency ofNatural Resources 

• Sam Ricketts, Director, Washington, DC Office of Washington State Governor Jay Inslee 

• Vicki Arroyo, Executive Director, Georgetown Climate Center 

• Gabriel Pacyniak, Associate, Georgetown Climate Center 

• Lissa Lynch, Associate, Georgetown Climate Center 
Date: -ry I~~ 

Meeting: Cff f~~ 

Rule(s) Discussed: 

Written Materials? Yes/No 

Name Organization Phone Number 

[;~[(, :::\o if /\l S o AJ ./Uf-£C4 ?o 3,- Yo j? ?..J -- __... 

~o/1-v /V o _/,(J)C /l./!Z£~19 7 oJ ~ 9o?-S'? CJJ> 

jZ1--j JJ~(v.e'7 ~,4- 2.- 2 ..-? 'TY- 9'(2( 

~0( 

( 

G~A~ PIAf:P V\S <:.-/fi !*if/¥\'¥\ ef(if s-6 Y - ST;J>;;L
---

---

# EXHIBIT 13

# CERTIFICATION OF PERIODIC FINANCIAL REPORTSUNDER 18 U.S.C 1350

In connection with the Annual Report
on Form 20-F of NUR Macroprinters Ltd. for the year ended December 31, 2004, as filed with
the Securities and Exchange Commission on the date hereof (the Report), the
undersigned hereby certify that:

|A) | The Report containing the financial statements fully complies with the
          requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934;
          and
|-- | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|B) | Information contained in the Report fairly presents, in all material respects,
          the financial condition and results of operations of the issuer.
|-- | ---------------------------------------------------------------------------------------------------------------------------------------------------------

| |  | /s/ David Amir
David AmirPresident and Chief Executive Officer
| |  | ----------------------------------------------------------------------------

| |  | /s/ David Seligman
David SeligmanChief Financial Officer
| |  | ----------------------------------------------------------------------

Date: July 13, 2005



---

---
```

[Congressional Bills 115th Congress]
[From the U.S. Government Publishing Office]
[H. Res. 619 Engrossed in House (EH)]

<DOC>
H. Res. 619

                In the House of Representatives, U. S.,

                                                     November 15, 2017.
    Resolved, That upon adoption of this resolution it shall be in order to 
consider in the House the bill (H.R. 1) to provide for reconciliation pursuant 
to title II of the concurrent resolution on the budget for fiscal year 2018. All 
points of order against consideration of the bill are waived. In lieu of the 
amendment in the nature of a substitute recommended by the Committee on Ways and 
Means now printed in the bill, an amendment in the nature of a substitute 
consisting of the text of Rules Committee Print 115-39 shall be considered as 
adopted. The bill, as amended, shall be considered as read. All points of order 
against provisions in the bill, as amended, are waived. The previous question 
shall be considered as ordered on the bill, as amended, and on any further 
amendment thereto, to final passage without intervening motion except: (1) four 
hours of debate equally divided and controlled by the chair and ranking minority 
member of the Committee on Ways and Means; and (2) one motion to recommit with 
or without instructions. Clause 5(b) of rule XXI shall not apply to the bill or 
amendments thereto.
    Sec. 2.  Upon passage of H.R. 1, the amendment to the title of such bill 
recommended by the Committee on Ways and Means now printed in the bill shall be 
considered as adopted.
    Sec. 3. On any legislative day during the period from November 17, 2017, 
through November 27, 2017--
    (a) the Journal of the proceedings of the previous day shall be considered 
as approved; and
    (b) the Chair may at any time declare the House adjourned to meet at a date 
and time, within the limits of clause 4, section 5, article I of the 
Constitution, to be announced by the Chair in declaring the adjournment.
    Sec. 4.  The Speaker may appoint Members to perform the duties of the Chair 
for the duration of the period addressed by section 3 of this resolution as 
though under clause 8(a) of rule I.
            Attest:

                                                                          Clerk.
```
<PAGE>
 
                                                                    EXHIBIT 23.1



              CONSENT OF ERNST & YOUNG LLP, INDEPENDENT AUDITORS


We consent to the incorporation by reference in the Registration Statements 
(Form S-3 No. 333-59861 and Form S-8 Nos. 333-00436 and 333-50983) pertaining to
certain shares of KeraVision, Inc. common stock issuable to the holders of 
Series B convertible preferred stock, the 1997 Employee Stock Option Plan, the 
1995 Director's Stock Option Plan, the 1995 Employee Stock Purchase Plan, the 
1995 Stock Option Plan and the 1987 Stock Option Plan of KeraVision, Inc. of our
report dated February 3, 1999, except for Note 9 as to which the date is March 
25, 1999, with respect to the consolidated financial statements of KeraVision, 
Inc. included in its Annual Report (Form 10-K/A) for the year ended December 31,
1998.



                                                   /s/ Ernst & Young LLP

San Jose, California
April 30, 1999
§ 182.3731 Sodium ascorbate. ( a ) *Product.* Sodium ascorbate.
( b ) *Conditions of use.* This substance is generally recognized as safe when used in accordance with good manufacturing practice.
Exhibit 99.1


Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Annual Report on Form 10-KSB of NatureWell, Incorporated
(the "Company") for the period ended June 30, 2002 as filed with the Securities
and Exchange Commission on the date hereof (the "Report"), I, James R. Arabia,
President and Chief Executive Officer of the Company, certify, pursuant section
906 of the Sarbanes-Oxley Act of 2002, that:

(1)
the Report fully complies with the requirements of section 13(a) or 15(d) of
the Securities Exchange Act of 1934; and

(2)
the information contained in the Report fairly presents, in all material
respects, the financial condition, and results of operations of the Company.

/s/ James R. Arabia
----------------------
James R. Arabia
Chairman of Board
and Chief Executive Officer
October 15, 2003


In connection with the Annual Report on Form 10-QSB of NatureWell, Incorporated
(the "Company") for the period ended June 30, 2002 as filed with the Securities
and Exchange Commission on the date hereof (the "Report"), I, Robert T.
Malasek, Treasurer and Chief Financial Officer of the Company, certify,
pursuant section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)
the Report fully complies with the requirements of section 13(a) or 15(d) of
the Securities Exchange Act of 1934; and

(2)
the information contained in the Report fairly presents, in all material
respects, the financial condition, and results of operations of the Company.


/s/ Robert Malasek
-------------------
Robert T. Malasek
Treasurer, and Chief Financial Officer
(Principal Financial and Accounting Officer)
October 15, 2003
### Geology and ground-water resources of the Dalles region, Oregon

By: A. M. Piper

                            https://doi.org/10.3133/wsp659B

#### Links

-                                                                                                                             Document:                                                                                                                                                                                                                                                  **Report**                                                                                                     (12243 pdf)                                                                                                                                     
- Plate:  **Plate 11**                            (19127 pdf)                        
- Download citation as:  RIS                         |                         Dublin                            Core

#### Abstract

No abstract available.

Part or all of this report is presented in Portable Document Format                        (PDF). For best results viewing and printing PDF documents, it is recommended that you download                        the documents to your computer and open them with Adobe Reader. PDF documents opened from your                        browser may not display or print as intended. Download the latest version of Adobe Reader, free of charge. More information                        about viewing, downloading, and printing report files can be found at the common download problems FAQ.
Editorial Note on Part 316
Editorial Note: Nomenclature changes to part 316 appear at 69 FR 13717, Mar. 24, 2004.

§ 316.31 Scope of orphan-drug exclusive approval. ( a ) FDA may approve a sponsor's marketing application for a designated orphan drug for use in the rare disease or condition for which the drug was designated, or for select indication(s) or use(s) within the rare disease or condition for which the drug was designated. Unless FDA previously approved the same drug for the same use or indication, FDA will not approve another sponsor's marketing application for the same drug for the same use or indication before the expiration of 7 years from the date of such approval as stated in the approval letter from FDA, except that such a marketing application can be approved sooner if, and at such time as, any of the following occurs: ( 1 ) Withdrawal of exclusive approval or revocation of orphan-drug designation by FDA under any provision of this part; or
( 2 ) Withdrawal for any reason of the marketing application for the drug in question; or
( 3 ) Consent by the holder of exclusive approval to permit another marketing application to gain approval; or
( 4 ) Failure of the holder of exclusive approval to assure a sufficient quantity of the drug under section 527 of the act and § 316.36.
( b ) Orphan-drug exclusive approval protects only the approved indication or use of a designated drug. If such approval is limited to only particular indication(s) or uses(s) within the rare disease or condition for which the drug was designated, FDA may later approve the drug for additional indication(s) or uses(s) within the rare disease or condition not protected by the exclusive approval. If the sponsor who obtains approval for these new indication(s) or uses(s) has orphan-drug designation for the drug for the rare disease or condition, FDA will recognize a new orphan-drug exclusive approval for these new (not previously approved) indication(s) or use(s) from the date of approval of the drug for such new indication(s) or use(s).
( c ) If a sponsor's marketing application for a drug product is determined not to be approvable because approval is barred under section 527 of the Federal Food, Drug, and Cosmetic Act until the expiration of the period of exclusive marketing of another drug, FDA will so notify the sponsor in writing.
[57 FR 62085, Dec. 29, 1992, as amended at 78 FR 35134, June 12, 2013]
Exhibit 32.2  FIRST
MARINER BANCORP
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002  Pursuant to, and for
purposes only of, 18 U.S.C. § 1350, I, Mark A. Keidel, Chief Financial
Officer of First Mariner Bancorp (the Company) hereby certify that (i) the
Annual Report of the Company on Form 10-K for the year ended December 31,
2008 filed with the Securities and Exchange Commission (the Report) fully
complies with the requirements of Section 13(a) or 15(d) of the
Securities Exchange Act of 1934, and (ii) information contained in the
Report fairly presents, in all material respects, the financial condition and
results of operations of the Company.   Dated: March 31,
  2009
  /s/ Mark A. KeidelMark A. KeidelChief Financial Officer
Exhibit






Exhibit 10.2


AMENDMENT TO THE
VIACOM EXCESS 401(K) PLAN FOR DESIGNATED SENIOR EXECUTIVES


1.    Effective as of March 13, 2017, Section 2.4 of the Plan is amended to read in its entirety as follows:


2.4    Committee.  The term "Committee" means the Retirement Committee appointed hereunder.  The Committee may act on its own behalf or through the actions of a duly authorized delegate or delegates.


2.    Effective as of March 13, 2017, Section 10.1 of the Plan is amended to read in its entirety as follows:


10.1    Committee.  This Plan will be administered by the Committee as an unfunded plan that is not intended to meet the qualification requirements of Section 401(a) of the Code.  The Committee shall consist of the Executive Vice President/Chief Administrative Officer, the Senior Vice President/Head of Compensation & Benefits and Deputy General Tax Counsel, and the Senior Vice President/Compensation and Benefits; provided, however, that the Executive Vice President/Chief Administrative Officer may add members and may remove members.  If there is no employee holding such title, the person acting in that capacity or holding a successor title, as appropriate, shall serve in that position on the Committee (but if such person is already a member, he/she shall have only one vote).